4565 Nxera Pharma
- 1053
- +31+3.03%
Nxera Pharma News
Nxera Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Stocks that moved the previous day part 1: Trousse OP, Celest, Maruichi Steel Pipe etc.
Stock Name <Code> Closing Price on the 9th ⇒ Change from the previous day Inspec <6656> 674 +4. Operating profit for the first half turned from a loss of 0.115 billion yen in the first quarter to a profit of 0.001 billion yen. It started to rise but lost momentum. Miroku <7983> 1169 -7624. Performance and dividend forecasts for the fiscal year ending October 24 have been revised downward. Isle <3854> 3000 -145. Operating profit decreased by 5.9% in the first quarter. Daiwa Can <3816> 1105 -89. Operating profit decreased by 29.5% in the first quarter. Tomita Electric <68
Nxera Pharma Begins Key Insomnia Drug Trial in South Korea
Open H, Ship HD, etc. (additional) Rating
Upgrade - Bullish code stock name securities company previously changed afterwards --------------------------------------------- <2413> M3 City "2" "1" <4565> Nexera Pharma City "2" "1" <7269> Suzuki JPM "Neutral" "Overweight" Downgrade - Bearish code stock name securities company previously changed afterwards --------------------------
Rating [security companies rating]
Upgraded - Bullish Code Stock Name Securities Company Previous After Change -------------------------------------------------- <3110> Nittohobo Tokai Tokyo "Neutral" "Out P" <9005> Tokyu SBI "Hold" "Buy" <7269> Suzuki JP Morgan "Neutral" "Over W" <2413> Emisuri City "Hold" "Buy" <4565> Nexus Era P City "Hold"
Nxera Pharma Gains Milestone Payment in Sleep Disorder Collaboration
Stocks that moved the previous day part2 include Nippon Ham, Taiyo Koki, Fuji Kogyo E&C, etc.
Stock name <Code> 5-day closing price⇒Day-over-day change BIPROGY <8056> 4420 -3187-Forecasted decrease in ordinary income for the September period. Nippon Ham <2282> 4754 -516Negative views such as sluggish improvement in revenue of processed business. Tokyo Electron Devices <2760> 3065 -265Negative sentiment towards double-digit operating profit decline in the first half results. Rigaku <268A> 1200 -50Majority favors selling due to awareness of overhead resistance. Nexela Pharma <4565> 1174 -397-9
Nxera Pharma and Antiverse Enter Collaboration To Design Novel GPCR-Targeted Antibody Therapeutics Using Generative AI
Sumitomo Electric, Mabuchi, etc. (Additional) Rating
Upgrade - Bullish Code Stock Name Securities Company Previous After Change ---------------------------------- <6080> M&A Capcom Maclory "Under P" "Out P" <6752> Panasonic HD Maclory "Neutral" "Out P" Target Stock Price Change Code Stock Name Securities Company Previous After Change ----------------------------------
November 5th [Today's Investment Strategy]
Specializing in clutches for motorcycles and autos.
Focus on FCC and Organo, are DMG Mori Seiki and Yamaha weak?
In the US stock market on the 4th, the dow jones industrial average closed down 257.59 points at 41,794.60, the nasdaq composite index fell 59.93 points to 18,179.98, and the chicago nikkei 225 futures were 255 yen higher at 38,375 yen than osaka midday trading. The exchange rate is 1 dollar = 152.10-20 yen. In today's Tokyo market, FCC <7296> announced a 55.3% increase in operating profit for the first half, implemented commemorative dividends, and also announced a share buyback with a limit of 2.5% of the issued shares, with a 2.3% increase in operating profit for the first half and an increase in issued shares of 1.
KDDI announces a 2.3% increase in operating profit in the second quarter to 573 billion yen, along with a share buyback and split.
KDDI<9433> announced its financial results for the second quarter of the fiscal year ending March 2025, with revenue increasing by 2.8% year-on-year to 2 trillion 855.7 billion 13 million yen, and operating profit increasing by 2.3% to 573 billion 86 million yen. The non-communications sectors such as enterprise digital transformation (DX) support services and finance performed well. The financial estimates for the fiscal year ending in March 2025 remain unchanged. Additionally, up to 100 billion yen, equivalent to 1.39% of the total number of issued shares (excluding treasury stock), is 2800.
Nxera Pharma: Business highlights and consolidated financial results for the 3rd quarter (January-September) of the fiscal year ending 2024/12
Nxera Pharma: Summary of financial results for the 3rd quarter of the fiscal year ending 2024/12 [IFRS] (consolidated)
Asahi Kasei, TDK, Mitsui Chemicals, kddi corporation (1st day)
※Please note that the above calendar is subject to change depending on the company's circumstances.---------------------------------------November 1st (Friday)＜2229＞Calbee ＜2282＞Nippon Ham＜2296＞Itoham Yonekyu Holdings ＜2349＞NIID ＜2440＞Gurunavi ＜2480＞Sysmex＜2551＞MarsaInc ＜2730＞Edion＜27
Cosmos Pharmaceuticals, Money Forward, etc. (additional) Rating
Upgrade - Bullish Code Stock Name Securities Company Original After Change -------------------------------------------------- <4902> Konica Minolta McCaulley "Neutral" "Outperform" Target Stock Price Change Code Stock Name Securities Company Original After Change -------------------------------------------------- <319
Nxera Pharma Wins Biotech Company of the Year and Financing Deal of the Year at the Citeline Japan Awards 2024
Stocks that moved the previous day part1: Ryomo Systems, Sansan, Disco, etc.
Obtained a domestic patent related to the method for predicting the efficacy of rheumatoid arthritis treatment drugs and evaluating the activity of rheumatoid arthritis.
Nxera Pharma to Host R&D Day 2024
CellSys hits new high [stocks hitting new highs and lows]
Top gainers on the TSE Prime are Wright Industries <1926> and Sumitomo Densetsu <1949> with a total of 39 stocks. Top losers on the TSE Prime are Nextage <3186> and Nexella Pharma <4565> with 5 stocks. "TSE Prime" "TSE Standard" "TSE Growth" new highs new lows new highs new lows new highs new lows 10/08 39 5 12 10 5 7 10/07 80 0
No Data